- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07569354
Recovery Among Older Adults Following Mild TBI
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Development of Alzheimer's disease and related dementias (ADRD) is multifactorial, and some causal factors can be influenced or modified. Recently, the Lancet Commission included traumatic brain injury (TBI) in its list of 12 key potentially modifiable ADRD risk factors. TBI is a very common injury among older adults, resulting in over 123,000 hospitalizations and 485,000 emergency department visits annually. Importantly, rates of TBI are rapidly increasing in this population. TBI results in cognitive impairment and increases risk for both Alzheimer's disease and fronto-temporal dementia. Furthermore, TBI can result in worsened health outcomes (e.g., poor cognitive and physical functioning, psychological distress, worsened sleep quality), which in turn increase risk for ADRD. Yet, despite the large public health impact of TBI among older adults, little is known about changes in cognition and related domains following discharge from acute care in this population. Although such information is urgently needed to guide rehabilitation, care planning, and promotion of optimal long-term recovery in this vulnerable population, these data are severely lacking in the literature. One major reason for this lack of knowledge is that most prior research on TBI has focused on younger adults. Unfortunately, many findings from younger adults do not generalize to older adults due to their higher comorbidity burden and poorer cognitive and physical functioning at discharge from acute care. The objective of the proposed research is to gain an in-depth understanding of recovery of cognition, psychological and physical functioning, and sleep quality following TBI among older adults. To achieve this objective, the investigators propose to conduct a prospective cohort study of 250 patients aged 65 years and older treated for mild TBI at the R Adams Cowley Shock Trauma Center or at one of six University of Maryland Medical System affiliated hospitals with follow-up at 2 weeks and 3, 6, and 12 months to complete three Specific Aims: 1) Assess recovery of cognitive functioning and identify predictors of poor recovery; 2) Assess recovery of physical and psychological functioning and sleep quality and identify predictors of poor recovery; 3) Identify interactions between recovery trajectories.
The significance of this research is that it will identify unique recovery patterns across important domains of functioning (including cognitive function) and factors that impact the course of recovery following mild TBI among older adults. Identification of individuals at risk for poor cognitive recovery following TBI will highlight a population at high risk of ADRD and would permit targeting those individuals with cognitive rehabilitation interventions, potentially reducing ADRD risk. The rationale for the proposed study is that early identification of patients with poorer recovery trajectories will permit development and targeting of appropriately timed interventions to mitigate ADRD risk and other adverse outcomes. The potential impact of this work is that it will generate new knowledge that will guide targeted treatment efforts and inform development of a geriatric-TBI focused rehabilitation intervention that will be the focus of a future R01 application.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jennifer Albrecht, PhD
- Numéro de téléphone: 410-706-0071 410-706-0071
- E-mail: jalbrecht@som.umaryland.edu
Sauvegarde des contacts de l'étude
- Nom: Michelle Newman, BSN
- Numéro de téléphone: 410-706-0933
- E-mail: mnewman@som.umaryland.edu
Lieux d'étude
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21201
- Recrutement
- University of Maryland, Baltimore
-
Contact:
- Jennifer Albrecht, PhD
- Numéro de téléphone: 410-706-0071 410-706-0071
- E-mail: jalbrecht@som.umaryland.edu
-
Contact:
- Michelle Newman, BSN
- Numéro de téléphone: 410-706-0071 410-706-0933
- E-mail: mnewman@som.umaryland.edu
-
Chercheur principal:
- Jennifer Albrecht, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria
- Aged 65 years or older
- Treated for mild TBI (defined below) at the R Adams Cowley Shock Trauma Center (STC) or at one of six University of Maryland Affiliated Hospitals within 72 hours of injury
Mild TBI was defined as:
- Traumatically induced physiological disruption of brain function, as manifested by at least one of the following 1) loss of consciousness ≤30 minutes, post-traumatic amnesia <24 hours, observed or self-reported transient confusion, disorientation, or impaired consciousness, or neurologic deficit as defined by a Glasgow Coma Scale (GCS) score of 13-14 on admission.
- GCS of 15 with no other evidence of mild TBI was also accepted with positive computed tomography image.
Exclusion criteria
- Injury to any other body region resulting in an abbreviated injury scale (AIS) score >2
- Anticipation that patient would not be ambulatory at 2-weeks post-injury
- History of dementia as determined by patient/proxy report or medical history
- Non-ambulatory pre-injury
- No available proxy
- Not English speaking
- Prisoners
- Live >55 miles from the STC.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Physical function
Délai: 2 weeks, 3, 6, and 12 months
|
Short Physical Performance Battery total score.
Range 0-12, Higher scores indicating better lower extremity function
|
2 weeks, 3, 6, and 12 months
|
|
Cognition
Délai: 2 weeks, 3, 6, and 12 months
|
Repeatable Battery for the Assessment of Neuropsychological Status total scaled score.
The scaled score is age adjusted with a mean of 100 and a standard deviation of 15.
Scores below 100 indicate poorer cognitive function relative to same-age peers.
|
2 weeks, 3, 6, and 12 months
|
|
Sleep quality
Délai: 2 weeks, 3, 6, and 12 months
|
Sleep duration in hours obtained from averaging values from participant's 1-week sleep diary.
Healthy sleep duration for older adults ranges between 7-8 hours per night.
|
2 weeks, 3, 6, and 12 months
|
|
Psychological function
Délai: 2 weeks, 3, 6, and 12 months
|
Geriatric depression scale, 15-item version.
Range 0-15 with higher scores indicating more severe symptoms of depression.
|
2 weeks, 3, 6, and 12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Physical Function
Délai: 2 weeks, 3, 6, and 12 months
|
The Four-Step Square Test, measured as the number of seconds needed to complete the test.
Values greater than 15 seconds are associated with increased fall risk.
|
2 weeks, 3, 6, and 12 months
|
|
Physical Function
Délai: 2 weeks, 3, 6, and 12 months
|
Activities of Daily Living, range 0-6 with higher scores indicating increased independence in activities of daily living
|
2 weeks, 3, 6, and 12 months
|
|
Physical Function
Délai: 2 weeks, 3, 6, and 12 months
|
Instrumental Activities of Daily Living, range 0-8 with higher scores indicating independence in instrumental activities of daily living
|
2 weeks, 3, 6, and 12 months
|
|
Physical Function
Délai: 2 weeks, 3, 6, and 12 months
|
Glasgow Outcomes Scale Extended, range 1-8 with higher scores indicating better recovery following traumatic brain injury
|
2 weeks, 3, 6, and 12 months
|
|
Cognition
Délai: 2 weeks, 3, 6, and 12 months
|
Repeatable Battery for the Assessment of Neuropsychological Status domain scores (delayed memory, immediate memory, visuo-spatial, language, attention).
The scaled score is age adjusted with a mean of 100 and a standard deviation of 15.
Scores below 100 indicate poorer cognitive function relative to same-age peers
|
2 weeks, 3, 6, and 12 months
|
|
Sleep Quality
Délai: 2 weeks, 3, 6, and 12 months
|
Insomnia Severity Index, range 0-28 with higher scores indicating increased symptoms of insomnia
|
2 weeks, 3, 6, and 12 months
|
|
Sleep Quality
Délai: 2 weeks, 3, 6, and 12 months
|
Pittsburgh Sleep Quality Index, range 0-21 with higher scores indicating poorer sleep quality
|
2 weeks, 3, 6, and 12 months
|
|
Psychological Function
Délai: 2 weeks, 3, 6, and 12 months
|
Hospital Anxiety and Depression Scale (anxiety sub-scale), range 0-21 with higher scores indicating increased symptoms of anxiety
|
2 weeks, 3, 6, and 12 months
|
|
Psychological Function
Délai: 2 weeks, 3, 6, and 12 months
|
Rivermead post-concussion symptoms questionnaire, range 0-64 with higher scores indicating more severe post-concussive symptoms.
|
2 weeks, 3, 6, and 12 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Jennifer Albrecht, PhD, University of Maryland
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HP-00100973
- R01AG076441 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .